- Spirea, a spin-out from the University of Cambridge, has developed a novel antibody drug conjugate platform and aims to reshape the future of cancer treatment.
- Spirea’s flexible technology achieves a high and stable drug-to-antibody ratio resulting in an improved therapeutic index to treat a wider range of patients
- Seed investment from Meltwind and Start Codon will accelerate in vivo proof-of-concept studies which are scheduled for completion by Q4 2020